Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec)

Acta Oncol. 2010;49(1):100-1. doi: 10.3109/02841860902897707.

Authors

Henrik Kindmark¹, Eva Tiensuu Janson, Bengt Gustavsson, Camilla Eriksson, Gunnel Larsson, Dan Granberg, Gordana Kozlowacki, Britt Skogseid, Staffan Welin, Kjell Oberg, Barbro Eriksson

Affiliation

¹ Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden.

PMID: 20100145
DOI: 10.3109/02841860902897707

No abstract available

Publication types

Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Carcinoid Tumor / drug therapy*
Carcinoid Tumor / metabolism
Endocrine Gland Neoplasms / drug therapy
Endocrine Gland Neoplasms / metabolism
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / metabolism
Humans
Imatinib Mesylate
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / metabolism
Piperazines / therapeutic use*
Proto-Oncogene Proteins c-kit / metabolism
Pyrimidines / therapeutic use*
Receptors, Platelet-Derived Growth Factor / metabolism

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Proto-Oncogene Proteins c-kit
Receptors, Platelet-Derived Growth Factor